Etanercept

  • TRADE NAME: Enbrel (Amgen, Wyeth)
  • INDICATIONS: Rheumatoid arthritis
  • CLASS: Cytokine inhibitor, TNF inhibitor
  • HALF-LIFE: 4–13 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Abatacept, Anakinra, Cyclophosphamide

PREGNANCY CATEGORY: B

Our database has 88 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile

or Take a FREE TRIAL

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
HEMATOLOGIC
OTIC
OCULAR
LOCAL
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of etanercept in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

  • Saved Searches
  • Watch Drug

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life Threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric